Dapagliflozin in heart failure

19th April 2021 by Dr Louise Hudman

Dapagliflozin in heart failure

This is a new guideline from NICE, published in February, advising that dapagliflozin can now be used in heart failure.

Isn’t dapagliflozin for diabetes?

Yes it is. It is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It reduces glucose reabsorption in the kidneys.

As it does this, it also reduces sodium reabsorption. This increased excretion leads to an osmotic diuresis.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

Related content

"I feel strongly that sessional GPs need an organisation solely focussed on representing their interests."

Dr Tim Cantor

See the full list of features within our NASGP membership plans

Membership